← Back to Search

Anticoagulant

Rivaroxaban for Cerebral Venous Thrombosis (SECRET Trial)

Phase 2
Waitlist Available
Led By Thalia S Field, MD FRCPC
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 180 or 365 days
Awards & highlights

SECRET Trial Summary

This trial looks at whether a drug called rivaroxaban is safe to use for treating people with a condition called cerebral venous thrombosis.

Eligible Conditions
  • Cerebral Venous Thrombosis

SECRET Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~180 or 365 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 180 or 365 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Composite rate of all-cause mortality, symptomatic intracranial bleeding, major extracranial bleeding
Secondary outcome measures
All-cause mortality
Boston cookie theft picture description task
EuroQOL 5-Dimensions (EQ-5D) score
+13 more

Side effects data

From 2020 Phase 3 trial • 179 Patients • NCT02164578
2%
Hypertensive crisis
1%
Intervertebral disc protrusion
1%
Erysipelas
1%
Bile duct stone
1%
Diverticulitis
1%
Foot fracture
1%
Chest pain
1%
Nausea
1%
Vomiting
1%
Cerebrovascular accident
100%
80%
60%
40%
20%
0%
Study treatment Arm
Aspirin
Rivaroxaban

SECRET Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: RivaroxabanExperimental Treatment1 Intervention
Rivaroxaban
Group II: Standard of careActive Control1 Intervention
Unfractionated heparin Low-molecular weight heparin (dalteparin, enoxaparin, tinzaparin) Warfarin
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rivaroxaban
FDA approved

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,413 Previous Clinical Trials
2,466,906 Total Patients Enrolled
Thalia S Field, MD FRCPCPrincipal InvestigatorUniversity of British Columbia
1 Previous Clinical Trials
232 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we breaking new ground with this clinical trial?

"Rivaroxaban has undergone 141 clinical trials in the last 14 years across 51 countries and 606 cities. The first trial, which was sponsored by Ash Access Technology, concluded in 2006 after completing Phase 3 approval with 415 patients. Since then, there have been an additional 840 studies completed."

Answered by AI

Could you tell us about other similar research projects that have used Rivaroxaban?

"While first studied in 2006, rivaroxaban has undergone 840 completed clinical trials as of now. Additionally, there are currently 141 live studies being conducted with a large portion taking place in Hamilton, Ontario."

Answered by AI

To what medical conditions is Rivaroxaban commonly applied?

"Rivaroxaban is most commonly used for treatment of general surgery. It can also be administered to treat other conditions including medical devices, systemic embolism, unstable angina pectoris."

Answered by AI

How many hospitals or research centers are participating in this clinical trial?

"This study is currently underway at 10 different research centres, some of which are in Hamilton, Kingston and Edmonton. If you choose to participate in this trial, it would be best to select the location nearest you to limit travel commitments."

Answered by AI

What risks does Rivaroxaban pose to patients?

"While there is some data backing up Rivaroxaban's safety, it only received a score of 2 because Phase 2 trials have yet to establish efficacy."

Answered by AI

Can patients enroll in this trial at present?

"This study, which was originally posted on March 12th 2019 according to clinicaltrials.gov, is looking for patients. The last update to the posting was on September 27th 2021."

Answered by AI

How many individuals are included in the research?

"That is correct. The information available on clinicaltrials.gov reveals that this research project, which was first advertised on March 12th 2019, is still recruiting patients. They are looking for 50 individuals total at 10 different trial sites."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study of Rivaroxaban for CeREbral Venous Thrombosis
Thalia Field 2019. "Study of Rivaroxaban for CeREbral Venous Thrombosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03178864.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top